For the second quarter of 2026, analysts expect Azitra Inc to report a loss of $0.21 per share on zero revenue, reflecting its status as a clinical-stage biotechnology company. The current stock price of approximately $0.34 remains significantly below the average analyst price target of $10.00, highlighting a high-risk, high-reward sentiment among the few firms covering the ticker.
Investors are primarily focused on the clinical progress of ATR-12, the company's lead genetically modified live biotherapeutic product for Netherton syndrome. Management is expected to provide updates on Phase 1b trial enrollment and the projected timeline for interim safety and efficacy data. Additionally, the company’s cash runway remains a critical concern, as shareholders look for clarity on funding sufficiency through the next major clinical milestones.